Industry Updates for the Psychedelics World

Psychedelics News

Industry

2 Jun 2023

Beckley Waves Establishes Psychedelics Ethics Council to Guide Industry Standards and Best Practices

The New Ethics Council will Work Alongside Beckley Waves to set the Standard for Sustainable and Ethical Operations in the Burgeoning Psychedelics Sector...

By Microdose NewsDesk

Industry

1 Jun 2023

Compass Pathways’ COMP360 Produces 50% Long-Term Depression Remission in Cancer Patients

Late last week we received news that Compass Pathways' psilocybin compound COMP360 produced extremely positive results in alleviating depression results in cancer patients....

By Jason Najum

Industry

26 May 2023

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application...

By Microdose

Industry

26 May 2023

Small Pharma Expands Intellectual Property Portfolio

Small Pharma announces significant developments In Intellectual Property Portfolio...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

19 May 2023

Terran Biosciences Discovers New Psilocybin Salts and Polymorphs; Publishes Patent Application

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA...

By Microdose NewsDesk

Industry

18 May 2023

MindMed Announces Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed announced that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed....

By Microdose NewsDesk

Industry

11 May 2023

$3,500: The Cost of Treatment in America’s First Legal Psilocybin Center

Oregon has just opened the US's first licensed treatment center. Prices hit $3,500 per treatment. This is a first look at the financial realities facing providers and patients....

By Jason Najum

Industry

10 May 2023

Cybin Doses Last Patient in Part B of Phase 1 DMT Trial

Cybin Inc. announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. With the...

By Microdose NewsDesk

Industry

9 May 2023

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Delix Therapeutics announced the regulatory approval and initiation of recruitment of a phase I clinical trial of lead candidate, DLX-001, a non-hallucinogenic psychoplastogen....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result